Skip to content

Coverage & Prior Authorization

Cleo helps you with the entire prior authorization workflow—from checking if PA is required to generating appeal letters with verifiable citations from the patient’s records.

Cleo has access to the CMS Medicare Part D formulary database—over 1.3 million drug entries across hundreds of insurance plans. When you ask about a medication, Cleo checks:

  • Prior Authorization — Is PA required? What percentage of plans require it?
  • Step Therapy — Must the patient try other medications first?
  • Quantity Limits — Are there dispensing restrictions?
  • Tier Level — Generic, preferred brand, specialty, etc.

In the Cleo side panel, you can ask questions like:

QuestionWhat You’ll Learn
”Does Ozempic require prior auth?”PA requirements across plans
”What tier is metformin?”Formulary tier distribution
”Check coverage for Eliquis”Full coverage summary
”Is step therapy required for Humira?”Step therapy status

When you ask about a medication, Cleo provides a summary like:

Formulary Coverage Summary (100 plans checked):
⚠️ Prior Authorization: REQUIRED in 85% of plans
✅ Step Therapy: Not required
📊 Quantity Limits: 4 pens per 28 days
Tier Distribution:
Tier 3 (Preferred Brand): 15 plans
Tier 5 (Specialty): 85 plans
TierDescriptionTypical Cost
Tier 1Preferred GenericLowest copay
Tier 2GenericLow copay
Tier 3Preferred BrandModerate copay
Tier 4Non-PreferredHigher copay
Tier 5SpecialtyHighest cost, often % coinsurance

Before prescribing a new medication, ask Cleo:

“Does [medication] require prior auth?”

This helps you anticipate insurance hurdles and discuss alternatives with the patient if needed.

When you need to submit a prior authorization, Cleo can search the patient’s records and generate a complete appeal letter with evidence.

When you ask Cleo to generate a PA letter, it automatically searches:

  • Medication history — Failed prior therapies, intolerance, adverse events
  • Uploaded documents — Faxed records, referral letters, specialist notes
  • Lab results — Supporting clinical evidence (A1c, eGFR, etc.)
  • Conditions — Relevant diagnoses with ICD-10 codes
  1. Navigate to the patient’s chart in your EHR

  2. Ask Cleo to generate a PA letter:

    • “Generate a PA letter for Wegovy”
    • “Write prior auth appeal for Ozempic for weight management”
    • “Create PA letter for Humira”
  3. Review the results — Cleo shows:

    • Evidence found (failed therapies, contraindications)
    • Supporting lab values
    • Missing evidence warnings
  4. Open in Hub — Click the attachment card to open the full PA Letter Editor

After Cleo generates a letter, click “Open in Hub” to access the full editing experience:

TabWhat You Can Do
Evidence ReviewToggle evidence to include/exclude, verify citations
Edit LetterModify the summary, conclusion, and sections
ExportCopy to clipboard or export as PDF

When you ask for a PA letter, Cleo generates something like:

WEGOVY
PA Required: YES (85% of plans)
Step Therapy: Required
EVIDENCE FOUND (4):
[!] Metformin (intolerance)
"Discontinued due to severe GI distress..."
Source: Epic - Primary Care, 2022-04-20
[X] Phentermine (contraindication)
"Stopped due to hypertension with BP >160/95..."
Source: Weight Management Clinic, 2023-05-15
--- DRAFT LETTER GENERATED ---
Citations: 4
[Open in Hub to review and edit →]

Coverage information comes from the CMS Medicare Part D formulary files, updated quarterly. This covers:

  • All Medicare Part D plans
  • RXCUI and NDC drug identifiers
  • Prior authorization flags
  • Step therapy requirements
  • Quantity limit details
  • Tier level assignments
  • Medicare Part D only — Commercial and Medicaid plans not yet included
  • Formulary data — Shows if PA is required, not the specific approval criteria
  • Quarterly updates — Data refreshed each quarter when CMS releases new files
  • Evidence quality — Letter quality depends on available patient records

For specific PA approval criteria (diagnosis requirements, prior medications tried, etc.), you may still need to check the payer’s clinical policy bulletins.